ArticleAntibiotics (Basel, Switzerland)2022
Niclosamide as a Repurposing Drug against
Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- The Pathogenesis, Clinical Features, and Treatment ofMicroorganisms · 2026Review
- Exploring the antibacterial and anti-biofilm properties of Diacerein against methicillin-resistantFrontiers in microbiology · 2025Article
- Clinical Characteristics and Risk Factors ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Article
- In vitro activity of the anthelmintic drug niclosamide against Sporothrix spp. strains with distinct genetic and antifungal susceptibility backgrounds.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Predicting lung exposure of intramuscular niclosamide as an antiviral agent: Power-law based pharmacokinetic modeling.Clinical and translational science · 2024Article
- Rising prevalence and drug resistance ofFrontiers in cellular and infection microbiology · 2024Review
- Drug Repurposing: Research Progress of Niclosamide and Its Derivatives on Antibacterial Activity.Infection and drug resistance · 2024Review
- Appraisal of Fungus-Derived Xanthoquinodins as Broad-Spectrum Anti-Infectives Targeting Phylogenetically Diverse Human Pathogens.Journal of natural products · 2023Article
- Prescription of Rifampicin forPathogens (Basel, Switzerland) · 2023Article
- Succinyl Chitosan-Colistin Conjugates as Promising Drug Delivery Systems.International journal of molecular sciences · 2022Article
- First Evidence of the Presence of the Causative Agent of Caseous Lymphadenitis-Pathogens (Basel, Switzerland) · 2022Article
- In Vitro Antibacterial and Anti-Inflammatory Activity ofPharmaceutics · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.